Poster presented on March 16, 2022 at the AD/PD™ 2022
Amyloid pathology-confirmed diagnosis of Alzheimer’s Disease has been an increasing area of focus. Assistance of diagnosis using amyloid PET imaging or cerebrospinal fluid biomarkers has been challenging to implement in clinical care due to cost, availability, and/or invasiveness of sampling. These hurdles can be circumvented by the assessment of biomarkers in the more easily accessible plasma.
The aim of this study was to evaluate a plasma pTau biomarker as a tool for predicting amyloid pathology.